|
private:theonehealthcompany
|
10090704
|
Apr 21st, 2024 12:00AM
|
FidoCure®
|
2.9K
|
27.00
|
Open
|
|
Apr 21st, 2024 08:05AM
|
Apr 21st, 2024 08:05AM
|
FidoCure is the first and only service to offer cancer care with a dual-focus approach that benefits both dogs and humans. Leveraging the genetic similarities between human and canine cancers, FidoCure offers targeted therapies that allow for more effective treatments extending dog lives by up to 3x. Through our Next Generation DNA Sequencing Test, the first of its kind to introduce human-grade targeted treatments to our canine companions, we have assembled the world's largest canine cancer genomics database which uses genomic testing to provide veterinarians with critical data, enabling them to tailor the most effective targeted therapies for each individual dog patient. You can view our peer reviewed research in Nature Precision Oncology Journal and Nature Scientific Reports.
FidoCure is proud to be leading precision medical research in canine oncology, and our team is committed to revolutionizing the way cancer care is delivered to dogs and humans alike. Our technology provides advanced diagnostics and facilitates access to precision medicines at the touch of a button.
FidoCure by the One Health Company is backed by premier biotech investors including Polaris Ventures, A16Z, and YCombinator. Our vision along with our stakeholders, is a world free of cancer achieved by cost-effective, personalized precision medicine for both humans and their canine companions.
Learn more at www.fidocure.com.
|
Open
|
Clinical Trials, Veterinary Clinical Trials, Saving Lives, Veterinary Oncology, Comparative Medicine, Animal Health, and AI Enabled Precision Medicine
|
Open
|
|
Palo Alto
|
California
|
US
|
|
|
One Health Company
|
|
|
|
private:theonehealthcompany
|
10090704
|
Apr 20th, 2024 12:00AM
|
FidoCure®
|
2.9K
|
27.00
|
Open
|
|
Apr 20th, 2024 07:02AM
|
Apr 20th, 2024 11:00PM
|
FidoCure is the first and only service to offer cancer care with a dual-focus approach that benefits both dogs and humans. Leveraging the genetic similarities between human and canine cancers, FidoCure offers targeted therapies that allow for more effective treatments extending dog lives by up to 3x. Through our Next Generation DNA Sequencing Test, the first of its kind to introduce human-grade targeted treatments to our canine companions, we have assembled the world's largest canine cancer genomics database which uses genomic testing to provide veterinarians with critical data, enabling them to tailor the most effective targeted therapies for each individual dog patient. You can view our peer reviewed research in Nature Precision Oncology Journal and Nature Scientific Reports.
FidoCure is proud to be leading precision medical research in canine oncology, and our team is committed to revolutionizing the way cancer care is delivered to dogs and humans alike. Our technology provides advanced diagnostics and facilitates access to precision medicines at the touch of a button.
FidoCure by the One Health Company is backed by premier biotech investors including Polaris Ventures, A16Z, and YCombinator. Our vision along with our stakeholders, is a world free of cancer achieved by cost-effective, personalized precision medicine for both humans and their canine companions.
Learn more at www.fidocure.com.
|
Open
|
Clinical Trials, Veterinary Clinical Trials, Saving Lives, Veterinary Oncology, Comparative Medicine, Animal Health, and AI Enabled Precision Medicine
|
Open
|
|
Palo Alto
|
California
|
US
|
|
|
One Health Company
|
|
|
|
private:theonehealthcompany
|
10090704
|
Apr 19th, 2024 12:00AM
|
FidoCure®
|
2.8K
|
27.00
|
Open
|
|
Apr 19th, 2024 09:33AM
|
Apr 19th, 2024 09:33AM
|
FidoCure is the first and only service to offer cancer care with a dual-focus approach that benefits both dogs and humans. Leveraging the genetic similarities between human and canine cancers, FidoCure offers targeted therapies that allow for more effective treatments extending dog lives by up to 3x. Through our Next Generation DNA Sequencing Test, the first of its kind to introduce human-grade targeted treatments to our canine companions, we have assembled the world's largest canine cancer genomics database which uses genomic testing to provide veterinarians with critical data, enabling them to tailor the most effective targeted therapies for each individual dog patient. You can view our peer reviewed research in Nature Precision Oncology Journal and Nature Scientific Reports.
FidoCure is proud to be leading precision medical research in canine oncology, and our team is committed to revolutionizing the way cancer care is delivered to dogs and humans alike. Our technology provides advanced diagnostics and facilitates access to precision medicines at the touch of a button.
FidoCure by the One Health Company is backed by premier biotech investors including Polaris Ventures, A16Z, and YCombinator. Our vision along with our stakeholders, is a world free of cancer achieved by cost-effective, personalized precision medicine for both humans and their canine companions.
Learn more at www.fidocure.com.
|
Open
|
Clinical Trials, Veterinary Clinical Trials, Saving Lives, Veterinary Oncology, Comparative Medicine, Animal Health, and AI Enabled Precision Medicine
|
Open
|
|
Palo Alto
|
California
|
US
|
|
|
One Health Company
|
|
|
|
private:theonehealthcompany
|
10090704
|
Apr 18th, 2024 12:00AM
|
FidoCure®
|
2.8K
|
27.00
|
Open
|
|
Apr 18th, 2024 08:12AM
|
Apr 19th, 2024 05:58AM
|
FidoCure is the first and only service to offer cancer care with a dual-focus approach that benefits both dogs and humans. Leveraging the genetic similarities between human and canine cancers, FidoCure offers targeted therapies that allow for more effective treatments extending dog lives by up to 3x. Through our Next Generation DNA Sequencing Test, the first of its kind to introduce human-grade targeted treatments to our canine companions, we have assembled the world's largest canine cancer genomics database which uses genomic testing to provide veterinarians with critical data, enabling them to tailor the most effective targeted therapies for each individual dog patient. You can view our peer reviewed research in Nature Precision Oncology Journal and Nature Scientific Reports.
FidoCure is proud to be leading precision medical research in canine oncology, and our team is committed to revolutionizing the way cancer care is delivered to dogs and humans alike. Our technology provides advanced diagnostics and facilitates access to precision medicines at the touch of a button.
FidoCure by the One Health Company is backed by premier biotech investors including Polaris Ventures, A16Z, and YCombinator. Our vision along with our stakeholders, is a world free of cancer achieved by cost-effective, personalized precision medicine for both humans and their canine companions.
Learn more at www.fidocure.com.
|
Open
|
Clinical Trials, Veterinary Clinical Trials, Saving Lives, Veterinary Oncology, Comparative Medicine, Animal Health, and AI Enabled Precision Medicine
|
Open
|
|
Palo Alto
|
California
|
US
|
|
|
One Health Company
|
|
|
|
private:theonehealthcompany
|
10090704
|
Apr 17th, 2024 12:00AM
|
FidoCure®
|
2.8K
|
27.00
|
Open
|
|
Apr 17th, 2024 09:33AM
|
Apr 17th, 2024 08:12PM
|
FidoCure is the first and only service to offer cancer care with a dual-focus approach that benefits both dogs and humans. Leveraging the genetic similarities between human and canine cancers, FidoCure offers targeted therapies that allow for more effective treatments extending dog lives by up to 3x. Through our Next Generation DNA Sequencing Test, the first of its kind to introduce human-grade targeted treatments to our canine companions, we have assembled the world's largest canine cancer genomics database which uses genomic testing to provide veterinarians with critical data, enabling them to tailor the most effective targeted therapies for each individual dog patient. You can view our peer reviewed research in Nature Precision Oncology Journal and Nature Scientific Reports.
FidoCure is proud to be leading precision medical research in canine oncology, and our team is committed to revolutionizing the way cancer care is delivered to dogs and humans alike. Our technology provides advanced diagnostics and facilitates access to precision medicines at the touch of a button.
FidoCure by the One Health Company is backed by premier biotech investors including Polaris Ventures, A16Z, and YCombinator. Our vision along with our stakeholders, is a world free of cancer achieved by cost-effective, personalized precision medicine for both humans and their canine companions.
Learn more at www.fidocure.com.
|
Open
|
Clinical Trials, Veterinary Clinical Trials, Saving Lives, Veterinary Oncology, Comparative Medicine, Animal Health, and AI Enabled Precision Medicine
|
Open
|
|
Palo Alto
|
California
|
US
|
|
|
One Health Company
|
|
|
|
private:theonehealthcompany
|
10090704
|
Apr 16th, 2024 12:00AM
|
FidoCure®
|
2.8K
|
27.00
|
Open
|
|
Apr 16th, 2024 07:07AM
|
Apr 16th, 2024 04:31PM
|
FidoCure is the first and only service to offer cancer care with a dual-focus approach that benefits both dogs and humans. Leveraging the genetic similarities between human and canine cancers, FidoCure offers targeted therapies that allow for more effective treatments extending dog lives by up to 3x. Through our Next Generation DNA Sequencing Test, the first of its kind to introduce human-grade targeted treatments to our canine companions, we have assembled the world's largest canine cancer genomics database which uses genomic testing to provide veterinarians with critical data, enabling them to tailor the most effective targeted therapies for each individual dog patient. You can view our peer reviewed research in Nature Precision Oncology Journal and Nature Scientific Reports.
FidoCure is proud to be leading precision medical research in canine oncology, and our team is committed to revolutionizing the way cancer care is delivered to dogs and humans alike. Our technology provides advanced diagnostics and facilitates access to precision medicines at the touch of a button.
FidoCure by the One Health Company is backed by premier biotech investors including Polaris Ventures, A16Z, and YCombinator. Our vision along with our stakeholders, is a world free of cancer achieved by cost-effective, personalized precision medicine for both humans and their canine companions.
Learn more at www.fidocure.com.
|
Open
|
Clinical Trials, Veterinary Clinical Trials, Saving Lives, Veterinary Oncology, Comparative Medicine, Animal Health, and AI Enabled Precision Medicine
|
Open
|
|
Palo Alto
|
California
|
US
|
|
|
One Health Company
|
|
|
|
private:theonehealthcompany
|
10090704
|
Apr 15th, 2024 12:00AM
|
FidoCure®
|
2.8K
|
27.00
|
Open
|
|
Apr 15th, 2024 09:53AM
|
Apr 15th, 2024 11:21PM
|
FidoCure is the first and only service to offer cancer care with a dual-focus approach that benefits both dogs and humans. Leveraging the genetic similarities between human and canine cancers, FidoCure offers targeted therapies that allow for more effective treatments extending dog lives by up to 3x. Through our Next Generation DNA Sequencing Test, the first of its kind to introduce human-grade targeted treatments to our canine companions, we have assembled the world's largest canine cancer genomics database which uses genomic testing to provide veterinarians with critical data, enabling them to tailor the most effective targeted therapies for each individual dog patient. You can view our peer reviewed research in Nature Precision Oncology Journal and Nature Scientific Reports.
FidoCure is proud to be leading precision medical research in canine oncology, and our team is committed to revolutionizing the way cancer care is delivered to dogs and humans alike. Our technology provides advanced diagnostics and facilitates access to precision medicines at the touch of a button.
FidoCure by the One Health Company is backed by premier biotech investors including Polaris Ventures, A16Z, and YCombinator. Our vision along with our stakeholders, is a world free of cancer achieved by cost-effective, personalized precision medicine for both humans and their canine companions.
Learn more at www.fidocure.com.
|
Open
|
Clinical Trials, Veterinary Clinical Trials, Saving Lives, Veterinary Oncology, Comparative Medicine, Animal Health, and AI Enabled Precision Medicine
|
Open
|
|
Palo Alto
|
California
|
US
|
|
|
One Health Company
|
|
|
|
private:theonehealthcompany
|
10090704
|
Apr 14th, 2024 12:00AM
|
FidoCure®
|
2.8K
|
27.00
|
Open
|
|
Apr 14th, 2024 05:55AM
|
Apr 14th, 2024 05:55AM
|
FidoCure is the first and only service to offer cancer care with a dual-focus approach that benefits both dogs and humans. Leveraging the genetic similarities between human and canine cancers, FidoCure offers targeted therapies that allow for more effective treatments extending dog lives by up to 3x. Through our Next Generation DNA Sequencing Test, the first of its kind to introduce human-grade targeted treatments to our canine companions, we have assembled the world's largest canine cancer genomics database which uses genomic testing to provide veterinarians with critical data, enabling them to tailor the most effective targeted therapies for each individual dog patient. You can view our peer reviewed research in Nature Precision Oncology Journal and Nature Scientific Reports.
FidoCure is proud to be leading precision medical research in canine oncology, and our team is committed to revolutionizing the way cancer care is delivered to dogs and humans alike. Our technology provides advanced diagnostics and facilitates access to precision medicines at the touch of a button.
FidoCure by the One Health Company is backed by premier biotech investors including Polaris Ventures, A16Z, and YCombinator. Our vision along with our stakeholders, is a world free of cancer achieved by cost-effective, personalized precision medicine for both humans and their canine companions.
Learn more at www.fidocure.com.
|
Open
|
Clinical Trials, Veterinary Clinical Trials, Saving Lives, Veterinary Oncology, Comparative Medicine, Animal Health, and AI Enabled Precision Medicine
|
Open
|
|
Palo Alto
|
California
|
US
|
|
|
One Health Company
|
|
|
|
private:theonehealthcompany
|
10090704
|
Apr 13th, 2024 12:00AM
|
FidoCure®
|
2.8K
|
27.00
|
Open
|
|
Apr 13th, 2024 04:49AM
|
Apr 13th, 2024 04:50PM
|
FidoCure is the first and only service to offer cancer care with a dual-focus approach that benefits both dogs and humans. Leveraging the genetic similarities between human and canine cancers, FidoCure offers targeted therapies that allow for more effective treatments extending dog lives by up to 3x. Through our Next Generation DNA Sequencing Test, the first of its kind to introduce human-grade targeted treatments to our canine companions, we have assembled the world's largest canine cancer genomics database which uses genomic testing to provide veterinarians with critical data, enabling them to tailor the most effective targeted therapies for each individual dog patient. You can view our peer reviewed research in Nature Precision Oncology Journal and Nature Scientific Reports.
FidoCure is proud to be leading precision medical research in canine oncology, and our team is committed to revolutionizing the way cancer care is delivered to dogs and humans alike. Our technology provides advanced diagnostics and facilitates access to precision medicines at the touch of a button.
FidoCure by the One Health Company is backed by premier biotech investors including Polaris Ventures, A16Z, and YCombinator. Our vision along with our stakeholders, is a world free of cancer achieved by cost-effective, personalized precision medicine for both humans and their canine companions.
Learn more at www.fidocure.com.
|
Open
|
Clinical Trials, Veterinary Clinical Trials, Saving Lives, Veterinary Oncology, Comparative Medicine, Animal Health, and AI Enabled Precision Medicine
|
Open
|
|
Palo Alto
|
California
|
US
|
|
|
One Health Company
|
|
|
|
private:theonehealthcompany
|
10090704
|
Apr 12th, 2024 12:00AM
|
FidoCure®
|
2.8K
|
26.00
|
Open
|
|
Apr 12th, 2024 05:02AM
|
Apr 12th, 2024 01:57PM
|
FidoCure is the first and only service to offer cancer care with a dual-focus approach that benefits both dogs and humans. Leveraging the genetic similarities between human and canine cancers, FidoCure offers targeted therapies that allow for more effective treatments extending dog lives by up to 3x. Through our Next Generation DNA Sequencing Test, the first of its kind to introduce human-grade targeted treatments to our canine companions, we have assembled the world's largest canine cancer genomics database which uses genomic testing to provide veterinarians with critical data, enabling them to tailor the most effective targeted therapies for each individual dog patient. You can view our peer reviewed research in Nature Precision Oncology Journal and Nature Scientific Reports.
FidoCure is proud to be leading precision medical research in canine oncology, and our team is committed to revolutionizing the way cancer care is delivered to dogs and humans alike. Our technology provides advanced diagnostics and facilitates access to precision medicines at the touch of a button.
FidoCure by the One Health Company is backed by premier biotech investors including Polaris Ventures, A16Z, and YCombinator. Our vision along with our stakeholders, is a world free of cancer achieved by cost-effective, personalized precision medicine for both humans and their canine companions.
Learn more at www.fidocure.com.
|
Open
|
Clinical Trials, Veterinary Clinical Trials, Saving Lives, Veterinary Oncology, Comparative Medicine, Animal Health, and AI Enabled Precision Medicine
|
Open
|
|
Palo Alto
|
California
|
US
|
|
|
One Health Company
|
|
|